Display options
Cite
Gaebel K, Blackhouse G, Campbell K, et al. Intravenous immunoglobulin for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis. Open Med. 2010;4(3):e154-66
Gaebel, K., Blackhouse, G., Campbell, K., Robertson, D., Xie, F., Assasi, N., Chalk, C., Levine, M., & Goeree, R. (2010). Intravenous immunoglobulin for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis. Open medicine : a peer-reviewed, independent, open-access journal, 4(3), e154-66.
Gaebel, Kathryn, et al. "Intravenous immunoglobulin for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis." Open medicine : a peer-reviewed, independent, open-access journal vol. 4,3 (2010): e154-66.
Gaebel K, Blackhouse G, Campbell K, Robertson D, Xie F, Assasi N, Chalk C, Levine M, Goeree R. Intravenous immunoglobulin for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis. Open Med. 2010;4(3):e154-66. Epub 2010 Aug 24. PMID: 21687335; PMCID: PMC3090105.
Copy Download .nbib Format: NLM
Share it on

Open Med. 2010;4(3):e154-66. Epub 2010 Aug 24.

Intravenous immunoglobulin for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis.

Open medicine : a peer-reviewed, independent, open-access journal

Kathryn Gaebel, Gord Blackhouse, Kaitryn Campbell, Diana Robertson, Feng Xie, Nazila Assasi, Colin Chalk, Mitchell Levine, Ron Goeree

PMID: 21687335 PMCID: PMC3090105

Abstract

BACKGROUND: Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an acquired immune-mediated inflammatory disorder that targets the myelin sheaths of the peripheral nervous system. Intravenous immunoglobulin (IVIg) is a blood product containing immunoglobulin G pooled from many human donors. In fall 2008, CIDP became an approved indication for IVIg in the United States and Canada.

OBJECTIVE: To evaluate the clinical effectiveness and safety of IVIg for the treatment of CIDP through a systematic review of published randomized controlled trials.

METHODS: We searched the MEDLINE (1996-2009, including in-process and other non-indexed citations), Embase (1996-2009) and other databases through the Ovid interface. We applied a methodological filter to limit retrieval to controlled clinical trials, meta-analyses and systematic reviews, and health technology assessments. Retrieval was limited to studies involving humans, and no language restrictions were employed. We pooled extracted data to estimate the effect size of IVIg treatment based on the random-effects model.

RESULTS: We identified 9 unique randomized controlled trials. Of these, 3 compared IVIg therapy with an active comparator (plasma exchange, plasma exchange using extracorporeal immunoadsorption, oral prednisolone, respectively); the other 6 trials had placebo controls. No incremental benefit was seen in terms of primary outcomes for comparisons of IVIg therapy and an active comparator. Data from 4 of the 6 placebo-controlled trials were included in a meta-analysis. A significant improvement in disability (i.e., reduction in disability score) was found, with a standardized mean difference of 0.65 (95% confidence interval [CI] 0.23 to 1.08) in favour of IVIg. A pooled analysis of the proportion of patients with a response to treatment, as defined by the investigators of each of the trials, resulted in a risk ratio of 2.74 (95% CI 1.80 to 4.15) favouring IVIg.

INTERPRETATION: IVIg therapy was statistically superior to placebo in reducing disability and impairment among patients with CIDP. The effectiveness of IVIg was similar to that of the alternative treatment strategies of plasma exchange and oral prednisolone.

References

  1. Neurology. 2001 Feb 27;56(4):445-9 - PubMed
  2. Control Clin Trials. 1996 Feb;17(1):1-12 - PubMed
  3. Neurology. 1991 May;41(5):617-8 - PubMed
  4. Ann Neurol. 1994 Dec;36(6):838-45 - PubMed
  5. Muscle Nerve. 1982 Apr;5(4):291-301 - PubMed
  6. Lancet. 1978 Oct 7;2(8093):750-3 - PubMed
  7. Med Care. 1992 Jun;30(6):473-83 - PubMed
  8. Ann Neurol. 1982 Feb;11(2):136-41 - PubMed
  9. Clin Neurophysiol. 2007 Sep;118(9):1980-4 - PubMed
  10. Neurology. 1990 Feb;40(2):209-12 - PubMed
  11. Control Clin Trials. 1986 Sep;7(3):177-88 - PubMed
  12. J Neurol Neurosurg Psychiatry. 2007 Dec;78(12):1349-53 - PubMed
  13. Cochrane Database Syst Rev. 2005 Apr 18;(2):CD004429 - PubMed
  14. Muscle Nerve. 1991 Nov;14(11):1103-9 - PubMed
  15. J Neurol. 1996 Mar;243(3):280-5 - PubMed
  16. J Neurol Neurosurg Psychiatry. 1999 May;66(5):677-80 - PubMed
  17. Neurol Clin. 2007 Feb;25(1):71-87 - PubMed
  18. Brain. 1996 Aug;119 ( Pt 4):1067-77 - PubMed
  19. Neurology. 2003 Jun 10;60(11):1822-4 - PubMed
  20. Stat Med. 2001 Feb 28;20(4):641-54 - PubMed
  21. Muscle Nerve. 2002 Mar;25(3):370-7 - PubMed
  22. Ann Neurol. 2001 Aug;50(2):195-201 - PubMed
  23. N Engl J Med. 1984 Mar 22;310(12):762-71 - PubMed
  24. Lancet Neurol. 2008 Feb;7(2):136-44 - PubMed
  25. Lancet Neurol. 2009 Feb;8(2):158-64 - PubMed
  26. Lancet. 2002 Feb 16;359(9306):614-8 - PubMed
  27. Ann Neurol. 1999 Dec;46(6):910-3 - PubMed
  28. J Neurol Neurosurg Psychiatry. 1993 Jan;56(1):36-9 - PubMed
  29. Cochrane Database Syst Rev. 2009 Jan 21;(1):CD001797 - PubMed
  30. Neurology. 1990 Feb;40(2):327-8 - PubMed
  31. Ann Neurol. 1980 Dec;8(6):590-6 - PubMed
  32. Am J Hematol. 2005 Mar;78(3):216-20 - PubMed
  33. Stroke. 1988 May;19(5):604-7 - PubMed
  34. J Neuroimaging. 2005 Apr;15(2):188-92 - PubMed
  35. J Neurol Neurosurg Psychiatry. 2008 Sep;79(9):1040-3 - PubMed
  36. Transfus Apher Sci. 2005 Nov;33(3):317-24 - PubMed
  37. Pharmacoepidemiol Drug Saf. 2007 Sep;16(9):1038-47 - PubMed
  38. Eur J Neurol. 2001 Mar;8(2):157-65 - PubMed
  39. Psychiatry Clin Neurosci. 1995 Jun;49(3):169-74 - PubMed

Publication Types